RDY
Dr. Reddy's Laboratories Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$11.88
−0.75%Price chart
Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8
ValuationView details →
P/E (Fwd)
25.0x
EV/EBITDA
16.7x
Market Cap
$9.90B
MomentumView details →
1D Return
−0.75%
YTD Return
−15.74%
RSI (14)
34.4
ValuationView details →
P/E (Fwd)
25.0x
EV/EBITDA
16.7x
Market Cap
$9.90B
RSI (14)
34.4
MomentumView details →
1D Return
−0.75%
YTD Return
−15.74%
SummaryUpdated Jun 1, 2026
Dr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical company founded in 1984 and headquartered in Hyderabad, India. The company has evolved from a small startup into one of India's largest pharmaceutical companies, going public on the New York Stock Exchange in 2001. Dr. Reddy's operates as an integrated pharmaceutical company with a global presence, manufacturing and marketing generic drugs, active pharmaceutical ingredients, and developing proprietary products across multiple therapeutic areas including cardiovascular, gastrointestinal, oncology, and diabetes treatments.
Similar companies
Latest newsMore news →
Aspen Pharmacare is pursuing the market for generic semaglutide, having obtained regulatory approval in Canada and awaiting registration in about 20 countries including Brazil and South Africa.7d agoDr. Reddy's Laboratories launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials, a generic equivalent of Bridion, in the United States.36d ago